New vaccine strategy aims to shield spleenless adults from deadly infections
NCT ID NCT02052154
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a two-step vaccine approach in 70 adults who had their spleen removed. Participants received one shot of a conjugate vaccine followed by a second shot of a polysaccharide vaccine two months later. The goal was to see if this combination triggers a strong immune response against 9 types of pneumococcal bacteria that can cause serious infections. Results were measured by antibody levels in the blood one month after the second shot.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPLENECTOMIZED PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service des Maladies Infectieuses et Tropicales - Centre d'Infectiologie Necker-Pasteur, IHU Imagine - Hôpital Necker-Enfants
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.